What is Tempus?
Tempus operates at the critical intersection of machine learning, genomic diagnostics, and clinical data science. The company has developed a sophisticated platform that unifies disparate patient records with deep molecular sequencing data, enabling medical practitioners to move beyond traditional, one-size-fits-all treatment protocols. By utilizing advanced neural networks, the organization provides clinicians with actionable insights for oncology, cardiology, and neuropsychiatry, effectively mapping therapeutic correlations that were previously invisible. This data-driven approach positions Tempus as a foundational infrastructure provider for the future of personalized therapeutic interventions.
How much funding has Tempus raised?
Tempus has raised a total of $2.1B across 12 funding rounds:
Series B
$50M
Series C
$70M
Series D
$80M
Series E
$110M
Series F
$200M
Multiple Rounds
$550M
Other Financing Round
$275M
Stock Offering
$410.7M
Debt
$300M
Series B (2017): $50M, investors not publicly disclosed
Series C (2017): $70M supported by New Enterprise Associates and Revolution Growth
Series D (2018): $80M featuring Revolution Growth and T. Rowe Price
Series E (2018): $110M backed by Baillie Gifford, T. Rowe Price, New Enterprise Associates, and Revolution Growth
Series F (2019): $200M with participation from New Enterprise Associates, Novo Holdings, Franklin Templeton Investments, T. Rowe Price, Revolution Growth, and Baillie Gifford
Series G (2020): $200M led by Novo Holdings, Franklin Templeton, T. Rowe Price, NEA, and Baillie Gifford
Other Financing Round (2020): $100M, investors not publicly disclosed
Debt (2020): $250M, investors not publicly disclosed
Other Financing Round (2022): $275M backed by Ares Capital
Stock Issuance/Offering (2024): $410.7M, investors not publicly disclosed
Debt (2025): $300M led by Ares Management Corporation
Key Investors in Tempus
T. Rowe Price
A global asset management organization providing investment solutions through active management, fundamental research, and long-term perspectives.
New Enterprise Associates
A prominent venture capital firm established in 1977, focused on partnering with entrepreneurs to build transformative businesses.
Revolution Growth
A venture capital firm that invests in transformative technologies and supports visionary founders across diverse geographic regions.
What's next for Tempus?
With the successful completion of this major strategic investment, Tempus is well-positioned to scale its computational engine and expand its reach within the global healthcare ecosystem. The company's focus remains on refining its predictive modeling capabilities to further enhance diagnostic accuracy and therapeutic efficacy. As the enterprise matures, the continued support from top-tier institutional investors suggests a long-term commitment to establishing Tempus as the standard-bearer for AI-enabled clinical decision support, likely driving further innovation in how complex pathologies are managed and treated on a global scale.
See full Tempus company page
